CareDx, Inc
Financials
Valuation Metrics
CareDx, Inc's Market Cap is $2.78B. At end of 2025 it was $963M. Ranked #1792 of 3,121 in US market (top 57%), #647 of 1,463 on NASDAQ (top 44%), #107 of 205 in Health Care Equipment & Services (top 52%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.78B | US#1,792/3,121 Sec#107/205 |
| Revenue | $458M | US#2,299/3,121 Sec#143/205 |
| Net Income | $111M | US#1,582/3,121 Sec#79/205 |
| Total Assets | $533M | US#2,744/3,121 Sec#155/205 |
| Net Assets | $426M | US#2,338/3,121 Sec#125/205 |
| Employees | 763 | US#2,102/3,121 Sec#147/205 |
| Value | ||
| P/E | 25.05x | US#1,416/3,121 Sec#48/205 |
| P/B | 6.53x | US#2,415/3,121 Sec#150/205 |
| PEG | 0.22x | US#357/3,121 Sec#13/205 |
| P/S | 6.07x | US#2,446/3,121 Sec#160/205 |
| EV/EBITDA | 155.96x | US#2,470/3,121 Sec#139/205 |
| FCF Yield | 3.06% | US#1,821/3,121 Sec#105/205 |
| Profitability | ||
| ROE | 26.08% | US#379/3,121 Sec#19/205 |
| ROA | 20.83% | US#95/3,121 Sec#4/205 |
| Op. Margin | -0.92% | US#2,381/3,121 Sec#135/205 |
| Revenue Growth | 34.41% | US#361/3,121 Sec#23/205 |
| Earnings Growth | 114.80% | US#272/3,121 Sec#11/205 |
| Financial Health | ||
| Debt Ratio | 25.23% | US#280/3,121 Sec#29/205 |
| Total Debt | $19M | US#2,764/3,121 Sec#174/205 |
| FCF | $85M | US#1,804/3,121 Sec#105/205 |
| Cash | $374M | US#1,254/3,121 Sec#71/205 |
| Current Ratio | 4.58x | US#523/3,121 Sec#46/205 |
| Net Debt/EBITDA | -22.78x | US#14/3,121 Sec#1/205 |
| Performance | ||
| 1Y Return | 264.45% | US#32/3,121 Sec#4/205 |
| 1M Return | 15.74% | US#116/3,121 Sec#20/205 |
| From 52W High | -2.41% | US#88/3,121 Sec#16/205 |
| 1Y MDD | -23.64% | US#966/3,121 Sec#26/205 |
| Trading | ||
| Volume | 1,181,614 shares | US#1,602/3,121 Sec#99/205 |
| Trading Value | $64M | US#1,351/3,121 Sec#97/205 |
| Per Share | ||
| EPS | $2.15 | US#1,288/3,121 Sec#63/205 |
| BPS | $8.24 | US#1,979/3,121 Sec#114/205 |
Company Info
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.